Caribou Stops Its Clinical Pipeline

Company Caribou Biosciences Event Type Program discontinuation, workforce reduction and strategic review Modality Allogeneic genome-edited CAR-T Asset Vispacabtagene regedleucel (vispa-cel); CB-011 Target CD19 (vispa-cel); BCMA (CB-011) Disease Area B-cell malignancies; multiple myeloma Summary Source-gap catch-up for a 6 October disclosure. Caribou Biosciences discontinued both clinical-stage…